-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Trilaciclib in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trilaciclib in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trilaciclib in Triple-Negative Breast Cancer (TNBC) Drug Details: Trilaciclib (Cosela)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (Cytarabine Hydrochloride + Daunorubicin Hydrochloride) in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cytarabine Hydrochloride + Daunorubicin Hydrochloride) in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cytarabine Hydrochloride...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trilaciclib in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trilaciclib in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trilaciclib in Breast Cancer Drug Details: Trilaciclib (Cosela) is a potential antineoplastic...
-
Sector Analysis
NewUnited Kingdom (UK) Easter Market Analysis, Trends, Consumer Attitudes and Buying Dynamics, 2024 Update
The UK Easter 2024 report forms part of GlobalData's Retail Occasions series, and offers a comprehensive insight into the consumer dynamics and spending habits of UK consumers for Easter. The report analyses the major players, the main trends, and consumer attitudes. The proportion of consumers that stated that they bought something for Easter fell in 2024 , as fewer consumers chose to spend on the event. The proportion of Easter shoppers purchasing food & drink held up better than other...
-
Sector Analysis
United Kingdom (UK) Halloween – Analyzing Market, Trends, Consumer Attitudes and Major Players, 2023 Update
UK Halloween Market Report Overview The proportion of consumers buying any item for Halloween in 2023 has declined, falling to 40.2% versus 2022. This is reflected in both retail and leisure purchases decreasing this year. Food was the only category in which penetration increased year-on-year, as consumers opted for low-cost celebrations amid pressures on personal finances. Value for money and price were most important as consumers looked to reduce spending at Halloween in the UK. The United Kingdom (UK) Halloween...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trilaciclib in Metastatic Transitional (Urothelial) Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trilaciclib in Metastatic Transitional (Urothelial) Tract Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Trilaciclib in Metastatic Transitional (Urothelial) Tract Cancer Drug Details:Trilaciclib (Cosela)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cytarabine Hydrochloride + Daunorubicin Hydrochloride) in Relapsed Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.(Cytarabine Hydrochloride + Daunorubicin Hydrochloride) in Relapsed Acute Myeloid Leukemia Drug Details: Cytarabine hydrochloride and daunorubicin...
-
Company Profile
Finsbury Food Group PLC – Company Profile
Finsbury Food Group Ltd (Finsbury Food Group), formerly Finsbury Food Group PLC, is a speciality bakery manufacturer. The company's main activities involve the production of a broad range of high-quality bread, cake and bakery snack products. Its major products include bread, morning goods, cakes, sweet treats, speciality breads, buns, rolls, celebration cakes, snacks and gluten-free breads, morning goods and cakes. Finsbury Food Group's licensed brands includes Disney, Warner Bros, Nickelodeon, Hasbro, Mattel, Nintendo and Xbox, among others. The company’s products...
Add to Basket -
Sector Analysis
Healthy Snacks Market Size, Share, Trends and Analysis by Region, Products and Segment Forecast to 2030
Accessing the in-depth insights from the ‘Healthy Snacks’ report can help you: Make informed decisions about market entry, technology adoption, and project planning Identify your competitors' capabilities to stay ahead in the market Identify promising segments (products), growth trends, regional trends, and markets to expand your regional presence, product portfolio, and discover successful investment opportunities. Anticipate changes in demand and adjust your business development strategies. Identify ongoing potential projects across regions. How is our ‘Healthy Snacks’ report different from other reports in the market? The report...